Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01359
|
|||||
| Drug Name |
Triflupromazine
|
|||||
| Synonyms |
Adazine; Fluopromazine; Fluorofen; Neoprin; Nivoman; Psyquil; Siquil; Trifluopromazine; Triflupromazina; Triflupromazinum;Vesprin; Vetame; Fluopromazine monohydrochloride; Trifluopromazine hydrochloride; Triflupromazine [INN]; Triflupromazina [INN-Spanish]; Triflupromazinum [INN-Latin]; Vesprin (TN); Triflupromazine (USP/INN); N,N-Dimethyl-2-(trifluoromethyl)-10H-phenothiazine-10-propanamine; N,N-dimethyl-3-[2-(trifluoromethyl)phenothiazin-10-yl]propan-1-amine; N,N-dimethyl-3-[2-(trifluoromethyl)phenothiazin-10-yl]propan-1-amine hydrochloride; N,N-dimethyl-3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propan-1-amine; N,N-dimethyl-3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)-1-propanamine; 10-(3-(Dimethylamino)propyl)-2-(trifluoromethyl)phenothiazine; 10-3-(Dimethylamino)propyl-2-(trifluoromethyl)phenothiazine; 2-(Trifluoromethyl)promazine; 2-Trifluoromethyl-10-(gamma-dimethylaminopropyl)phenothiazine
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Psychosis [ICD11: 6A2Y] | Approved | [1] | |||
| Therapeutic Class |
Antipsychotic Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C18H19F3N2S
|
|||||
| Canonical SMILES |
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(F)(F)F
|
|||||
| InChI |
InChI=1S/C18H19F3N2S/c1-22(2)10-5-11-23-14-6-3-4-7-16(14)24-17-9-8-13(12-15(17)23)18(19,20)21/h3-4,6-9,12H,5,10-11H2,1-2H3
|
|||||
| InChIKey |
XSCGXQMFQXDFCW-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 146-54-3
|
|||||
| Pharmaceutical Properties | Molecular Weight | 352.4 | Topological Polar Surface Area | 31.8 | ||
| Heavy Atom Count | 24 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
5.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
5664289
, 7847456
, 8153424
, 10508360
, 11111873
, 11111874
, 11335983
, 11361222
, 11362929
, 11365491
, 11368053
, 11374201
, 11376215
, 11405424
, 11405821
, 11462194
, 11466081
, 11467201
, 11485862
, 11492556
, 11493909
, 14925496
, 24263033
, 29224607
, 46507344
, 47365232
, 47440302
, 47440303
, 47662324
, 47662325
, 47736524
, 48035163
, 48259273
, 48259274
, 48334534
, 48416663
, 49698933
, 50006493
, 50100355
, 50104262
, 50839748
, 56394865
, 57322847
, 85209834
, 90341005
, 103024193
, 103179080
, 103841663
, 103957782
, 104309608
|
|||||
| ChEBI ID |
ChEBI:9711
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Triflupromazine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.